SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending as it hits new all-time highs, fueled by optimism surrounding its robotaxi initiatives despite some concerns about sales and earnings. The stock's momentum has sparked discussions about its valuation, potential short squeezes, and the broader implications of autonomous driving technology, with many traders expressing strong bullish or bearish sentiments.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation around its potential acquisition of Warner Bros. Discovery, with community discussions focusing on whether Netflix will increase its offer to compete with Paramount.  Some traders believe Netflix is oversold, while others anticipate further declines depending on the deal's outcome; the community is closely watching for official news and potential market reactions.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid a hostile takeover bid for Warner Bros. Discovery ($WBD), challenging Netflix's ($NFLX) deal and sparking community debate about the best outcome. Discussions revolve around the financial implications, regulatory hurdles, and potential influence of figures like Trump and Ellison on the deal's outcome, with many viewing PSKY's all-cash offer as superior.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a recent surge, with community members drawing comparisons to SMX and emphasizing its potential in the robotics sector. The primary focus is on maintaining upward momentum, battling perceived short sellers, and removing stop losses. Speculation about a potential short squeeze and high after-hours targets are driving significant interest.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies

DBV Technologies ($DBVT) is trending due to positive Phase 3 trial data for its Viaskin Peanut patch in toddlers, showing promising results in treating peanut allergies. The community is discussing the potential for accelerated FDA approval and the patch's impact on the peanut allergy market, with some highlighting the unmet need for effective treatments and the potential for significant revenue. However, concerns remain around potential dilution and cash runway.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Shares of Childrens Place Inc are volatile as investors monitor late earnings filings and debate whether the company will announce preliminary results soon. The community is weighing potential outcomes, including bankruptcy, debt refinancing, or a possible sale, while also considering the high short interest. Some traders believe a short squeeze is possible, while others express concern over the lack of news.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

LEN is trending due to mixed reactions to earnings, with an EPS miss overshadowed by a revenue beat and positive Q3 outlook. The community is focused on the impact of affordability issues, mortgage rates, and the company's forward guidance. Discussions also involve broader market factors and analyst ratings.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending as the community discusses the potential impact of evolving government healthcare policies, particularly Affordable Care Act subsidies. Community members are analyzing the potential outcomes of current debates in the House and Senate, with some speculating on whether an extension of subsidies is likely. Bullish investors are optimistic about Centene's long-term prospects irrespective of near-term policy decisions.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid a potential bidding war between Netflix and Paramount, with community members weighing the pros and cons of each offer. Discussions revolve around deal structure, regulatory hurdles, and potential influence from figures like Trump. Some traders believe a higher bid is likely, while others express concerns about debt and market volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid mixed sentiment following news of a potential prediction market launch and commentary surrounding Donald Trump. The community is actively discussing the stock's valuation, political implications, and Trump's recent public statements, creating a volatile conversation around the stock's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

June 26, 2025<a target="_blank" rel="noopener noreferrer nofollow" href="https://jaguarhealth.gcs-web.com/node/15251/pdf">PDF Version</a>Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of valueSAN FRANCISCO, CA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 26, 2025 / <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue6">Jaguar Health, Inc.</a> (<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue7">NASDAQ:JAGX</a>) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset."Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue8">Canalevia</a>® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue9">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buea">https://jaguar.health</a>Napo Pharmaceuticals, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueb">www.napopharma.com</a>Napo Therapeutics, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buec">napotherapeutics.com</a>Magdalena Biosciences, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bued">magdalenabiosciences.com</a>Canalevia-CA1, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buee">canalevia.com</a>Visit the Make Cancer Less Shitty patient advocacy program on <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buef">Bluesky</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueg">X</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueh">Facebook</a> &amp; <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buei">Instagram</a>Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.CONTACT: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a> Jaguar-JAGXSOURCE:&nbsp;Jaguar Health, Inc. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-board-of-directors-authorizes-company-to-include-crypto-1043232">press release</a>

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Others

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share.&nbsp;Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares.&nbsp;These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright &amp; Co. holds exclusive placement agency responsibilities.Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022.&nbsp;<stembedurl>https://stocktwits.com/jimiinfinity/message/615411703</stembedurl>Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.<stembedurl>https://stocktwits.com/Torobravo_1/message/615384587</stembedurl>The stock has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

JAGX
Jaguar Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAGX News

JAGXJaguar Health Inc